A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.
A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.
Morningstar markets editor Jeremy Glaser looks at if the congressional supercommittee, Coach, Pfizer, Comcast, and Kraft can deliver the goods.
Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.
Good day everyone, and welcome to Pfizer s Third Quarter 2010 Earnings Conference Call. Today s call is being recorded.
Good day, everyone, and welcome to Pfizer s Fourth Quarter 2010 Earnings Conference Call. Today s call is being recorded.
©2012 Morningstar Advisor. All right reserved.